In the context of experimental and clinical pharmacology, the paper provides evidence for that use of Maxaquine, a fluoroquinolone agent, is effective in the combined therapy of tuberculosis. Indications for its clinical use, dosage, and administration rates have been defined. Treatment regimens for patients isolating drug-sensitive and drug-resistant Mycobacteria tuberculosis in the presence or absence of contaminant nonspecific respiratory infections are presented. The duration of combined therapy has been defined depending on the pattern of a process and comorbidity.